These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32827561)

  • 1. The integrated use of in silico methods for the hepatotoxicity potential of Piper methysticum.
    Tugcu G; Kırmızıbekmez H; Aydın A
    Food Chem Toxicol; 2020 Nov; 145():111663. PubMed ID: 32827561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats.
    Lim ST; Dragull K; Tang CS; Bittenbender HC; Efird JT; Nerurkar PV
    Toxicol Sci; 2007 May; 97(1):214-21. PubMed ID: 17329236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence.
    Teschke R; Qiu SX; Xuan TD; Lebot V
    Phytother Res; 2011 Sep; 25(9):1263-74. PubMed ID: 21442674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kava kava: examining new reports of toxicity.
    Clouatre DL
    Toxicol Lett; 2004 Apr; 150(1):85-96. PubMed ID: 15068826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro cytotoxicity of nonpolar constituents from different parts of kava plant (Piper methysticum).
    Jhoo JW; Freeman JP; Heinze TM; Moody JD; Schnackenberg LK; Beger RD; Dragull K; Tang CS; Ang CY
    J Agric Food Chem; 2006 Apr; 54(8):3157-62. PubMed ID: 16608246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kava hepatotoxicity: pathogenetic aspects and prospective considerations.
    Teschke R
    Liver Int; 2010 Oct; 30(9):1270-9. PubMed ID: 20630022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of commercial kava extracts and kavalactone standards for mutagenicity and toxicity using the mammalian cell gene mutation assay in L5178Y mouse lymphoma cells.
    Whittaker P; Clarke JJ; San RH; Betz JM; Seifried HE; de Jager LS; Dunkel VC
    Food Chem Toxicol; 2008 Jan; 46(1):168-74. PubMed ID: 17822821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kava hepatotoxicity: regulatory data selection and causality assessment.
    Teschke R; Wolff A
    Dig Liver Dis; 2009 Dec; 41(12):891-901. PubMed ID: 19477698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava).
    Unger M; Holzgrabe U; Jacobsen W; Cummins C; Benet LZ
    Planta Med; 2002 Dec; 68(12):1055-8. PubMed ID: 12494328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats.
    Yamazaki Y; Hashida H; Arita A; Hamaguchi K; Shimura F
    Food Chem Toxicol; 2008 Dec; 46(12):3732-8. PubMed ID: 18930106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel electrophilic metabolites of piper methysticum Forst (Kava).
    Johnson BM; Qiu SX; Zhang S; Zhang F; Burdette JE; Yu L; Bolton JL; van Breemen RB
    Chem Res Toxicol; 2003 Jun; 16(6):733-40. PubMed ID: 12807356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kava hepatotoxicity in traditional and modern use: the presumed Pacific kava paradox hypothesis revisited.
    Teschke R; Sarris J; Schweitzer I
    Br J Clin Pharmacol; 2012 Feb; 73(2):170-4. PubMed ID: 21801196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro inhibition of carboxylesterase 1 by Kava (Piper methysticum) Kavalactones.
    Melchert PW; Qian Y; Zhang Q; Klee BO; Xing C; Markowitz JS
    Chem Biol Interact; 2022 Apr; 357():109883. PubMed ID: 35278473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, in vitro, reactivity, and identification of 6-phenyl-3-hexen-2-one in human urine after kava-kava (Piper methysticum) ingestion.
    Zou L; Harkey MR; Henderson GL
    Planta Med; 2005 Feb; 71(2):142-6. PubMed ID: 15729622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst. f.).
    Anke J; Ramzan I
    J Ethnopharmacol; 2004 Aug; 93(2-3):153-60. PubMed ID: 15234747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward?
    Sarris J; Teschke R; Stough C; Scholey A; Schweitzer I
    Planta Med; 2011 Jan; 77(2):107-10. PubMed ID: 20814850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones.
    Nerurkar PV; Dragull K; Tang CS
    Toxicol Sci; 2004 May; 79(1):106-11. PubMed ID: 14737001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological Activity, Hepatotoxicity, and Structure-Activity Relationship of Kavalactones and Flavokavins, the Two Main Bioactive Components in Kava (
    Wang Y; Su C; Zhang B; Niu Y; Ren R; Zhao X; Yang L; Zhang W; Ma X
    Evid Based Complement Alternat Med; 2021; 2021():6851798. PubMed ID: 34471418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constituents in kava extracts potentially involved in hepatotoxicity: a review.
    Olsen LR; Grillo MP; Skonberg C
    Chem Res Toxicol; 2011 Jul; 24(7):992-1002. PubMed ID: 21506562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver transplantation and the use of KAVA: Case report.
    Becker MW; Lourençone EMS; De Mello AF; Branco A; Filho EMR; Blatt CR; Mallmann CA; Schneider M; Caregnato RCA; Blatt CR
    Phytomedicine; 2019 Mar; 56():21-26. PubMed ID: 30668342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.